- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12:46 | UK biotech poised for record VC year after maintaining recovery momentum | ||
| 11:46 | Lunit and Summit to evaluate pathology platform for tumour analysis | ||
| 10:46 | Pathos AI completes $237m Series E round to expand oncology pipeline | ||
| Fr | US targets Chinese biotech investment, but licensing deals remain exempt | ||
| Fr | Gilead spends $1.28bn on PepStar's potential Icotyde rival | ||
| Fr | Boehringer and Microsoft collaborate to explore AI in clinical research | ||
| Fr | Celltrion and Kaigene sign $580m licence deal for KG013 | ||
| Do | Roche's pharma sales grow 7% but pipeline trimmed down | ||
| Do | AstraZeneca bags another US indication for Ultomiris with IgAN approval | ||
| Do | Astellas and AI Proteins sign miniprotein therapeutics deal | ||
| Do | MSD's Keytruda and Padcev combination receives EC approval | ||
| Mi | FDA approves GSK's Hibsago as first functional cure for hepatitis B | ||
| Mi | AbbVie races into F1 as pharma companies continue push into sport | ||
| Mi | FDA approves Cosette's Evoxac oral solution for Sjögren's disease | ||
| Mi | MHRA revokes approval for Valneva's Ixchiq due to safety frailties | ||
| Mi | Sanofi and ScionxBio partner on mRNA therapies | ||
| Di | EyePoint halves workforce and ends Phase III trial early after endpoint miss | ||
| Di | Merck KGaA spends $1.3bn to buy siRNA specialist Silence Therapeutics | ||
| Di | Ambrose Healthcare fortifies rare disease pipeline on AM-Pharma takeover | ||
| 19.10. | Roche's Enspryng nets a second indication on FDA eye disease approval | ||
| 19.10. | MHRA could allow schools to hold reserves of nasal adrenaline spray | ||
| 19.10. | FDA approves Viatris' Ryzumvi for adult presbyopia | ||
| 19.10. | Estuary secures $103m to advance kidney disease gene therapies | ||
| 16.10. | Lilly's Foundayo wins EMA panel backing for obesity and type 2 diabetes | ||
| 16.10. | OrbiMed raises $3bn to back global life science players |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.